76
|
Jeraiby M, Sidi Yahya K, Depince-Berger AE, Lambert C. Microbicidal activity measured by flow cytometry: Optimization and standardization for detection of primary and functional deficiencies. J Immunol Methods 2017; 441:8-14. [DOI: 10.1016/j.jim.2016.09.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2016] [Revised: 08/11/2016] [Accepted: 09/26/2016] [Indexed: 01/26/2023]
|
77
|
Depince-Berger AE, Aanei C, Iobagiu C, Jeraiby M, Lambert C. New tools in cytometry. Morphologie 2016; 100:199-209. [PMID: 27369290 DOI: 10.1016/j.morpho.2016.05.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2016] [Revised: 04/12/2016] [Accepted: 05/18/2016] [Indexed: 06/06/2023]
Abstract
Cytometry aims to analyze cells, of any type, using dedicated instruments. The quantitative aspect makes flow cytometry (FCM) a good complementary tool for morphology. Most of the identification tools are based on immunostaining of cell structure details and more and more tools are available in terms of specificities and labels. FCM is under exponential development thanks to technical, immunological and data analysis progresses. Actual generations are now routinely using 6 to 10 simultaneous immuno-labeling on 20 to 100,000 cells, at high speed and short sample preparation and can easily detect rare events at frequency below 10-4 cells. Data interpretation is complex and requires expertise. Mathematical tools are available to support analysis and classification of cells based. Cells from tissues can also be analyzed by FCM after mechanical and or enzymatic separation, but in situ cells can also be analyzed with the help of cytometry. Very new instruments bring spectral analysis, image in flow and mass spectrometry. Medical applications are very broad, notably in hemopathies, immunology, solid tumors, but also microbiology, toxicology, drug discovery, food and environmental industry. But, the limit of FCM is its dependence on operator from sample preparation, instrument settings up to data analysis and a strong effort is now under progress for standardization and constitution of international data bank for references and education.
Collapse
|
78
|
Mawson PR, Lambert C. Challenges of operating a multi-species breeding-for-release facility at Perth Zoo, Australia. ACTA ACUST UNITED AC 2016. [DOI: 10.1111/izy.12150] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
79
|
Lannoy N, Lambert C, Farrugia A, Van Damme A, Hermans C. Usual and unusual mutations in a cohort of Belgian patients with hemophilia B. Thromb Res 2016; 149:25-28. [PMID: 27865967 DOI: 10.1016/j.thromres.2016.11.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2016] [Revised: 11/04/2016] [Accepted: 11/09/2016] [Indexed: 11/17/2022]
|
80
|
Lobet S, Lambert C, Hermans C. Stop only advising physical activity in adults with haemophilia… prescribe it now! The role of exercise therapy and nutrition in chronic musculoskeletal diseases. Haemophilia 2016; 22:e554-e556. [DOI: 10.1111/hae.13073] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/17/2016] [Indexed: 12/31/2022]
|
81
|
Schmidt A, Christiansen N, Alice L, O'Connor R, Lambert C, Cowlard J, Blakeley K, Keane C, Sharpe S, McLean M, Kalsi H, Brown S, Nwokoro C, Pao C. ePS02.6 Improving efficiency in an outpatient setting – Experience from a paediatric CF centre in East London. J Cyst Fibros 2016. [DOI: 10.1016/s1569-1993(16)30202-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
82
|
Buckley L, Webb R, Lambert C, Nyiri B, Gerig L. SU-F-J-52: A Novel Approach to X-Ray Tube Quality Assurance for CBCT Systems in Order to Better Assess the Patient Imaging Dose in a Large, Multi-Unit Treatment Facility. Med Phys 2016. [DOI: 10.1118/1.4955960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
83
|
Cole R, Gandhi J, Morris A, Lambert C, McCue A, Yin M, Laskar S, Smith A, Vega J, Gupta D. De Novo DQ Donor-Specific Antibodies Are Associated with Worse Outcomes Compared to Non-DQ DSA Following Heart Transplantation. J Heart Lung Transplant 2016. [DOI: 10.1016/j.healun.2016.01.114] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
84
|
Cole R, Gupta D, Lee J, Gandhi J, Lambert C, Garcia-Bengochea Y, Sandesara P, Yin M, Smith A, Laskar S, Morris A. ABO Blood Group and Bleeding Post-LVAD. J Heart Lung Transplant 2016. [DOI: 10.1016/j.healun.2016.01.717] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
85
|
Zimmermann M, Taussky D, Menkarios C, Vigneault É, Beauchemin MC, Bahary JP, Martin AAG, Diaz de Bedoya LV, Lambert C. Prospective Phase II Trial of Once-weekly Hypofractionated Radiation Therapy for Low-risk Adenocarcinoma of the Prostate: Late Toxicities and Outcomes. Clin Oncol (R Coll Radiol) 2016; 28:386-92. [PMID: 26782838 DOI: 10.1016/j.clon.2015.12.024] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2015] [Revised: 11/25/2015] [Accepted: 11/30/2015] [Indexed: 10/22/2022]
Abstract
AIMS To report the long-term toxicities and sexual quality of life of a once-weekly hypofractionated radiation therapy schedule for low-risk prostate cancer. MATERIALS AND METHODS A multi-institutional phase II trial was conducted, using a three-dimensional conformal radiation therapy (3D-CRT) approach for low-risk prostate cancer (T1a-T2a, Gleason ≤ 6 and prostate-specific antigen ≤ 10 ng/ml). Forty-five Gray (Gy) were delivered in nine fractions of 5 Gy given on a weekly basis. Acute and late genitourinary and gastrointestinal toxicities were graded according to the Radiation Therapy Oncology Group toxicity scale. Sexual function and sexual bother were assessed with the Expanded Prostate Cancer Index Composite (EPIC) questionnaire. RESULTS Between March 2006 and August 2008, 80 patients were treated, with a median age of 69 years (interquartile range 64-72). The median follow-up was 83 months (interquartile range 73-85 months). At 7 years, overall survival was 88%. No patients died of prostate cancer. Cumulative grade ≥2 genitourinary and gastrointestinal late toxicity was reported for 31.3% and 30% of our patients, respectively. Cumulative grade ≥3 genitourinary and gastrointestinal late toxicity was seen in 3.8% and 12.5% of cases, respectively. Late genitourinary grade 2 toxicity was correlated with the occurrence of acute genitourinary grade 2 toxicity (P = 0.006). The occurrence of late gastrointestinal toxicity was not correlated with acute gastrointestinal toxicity. Pre-treatment EPIC sexual function was low (37.5%) and the mean EPIC sexual function score at 7 years after treatment was 14%. On the other hand, pre-treatment EPIC sexual bother reached 80.5%, meaning little bother, and remained stable during follow-up. CONCLUSIONS Once-weekly 3D-CRT leads to excellent biochemical disease-free survival and acceptable toxicities. Pre-treatment EPIC sexual function dropped by 42% at 5 years of follow-up. This functional deficit did not bother patients, possibly due to the already low sexual function at baseline.
Collapse
|
86
|
Steeger M, Holzapfel M, Schmiedel A, Lambert C. Energy redistribution dynamics in triarylamine–triarylborane containing hexaarylbenzenes. Phys Chem Chem Phys 2016; 18:13403-12. [DOI: 10.1039/c6cp01923d] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Hexaarylbenzenes with triarylamine donors and triarylborane acceptors show rapid energy transfer (∼3 ps) as proved by pump–probe spectroscopy with fs-time resolution.
Collapse
|
87
|
Lambert C, Moos M, Schmiedel A, Holzapfel M, Schäfer J, Kess M, Engel V. How fast is optically induced electron transfer in organic mixed valence systems? Phys Chem Chem Phys 2016; 18:19405-11. [DOI: 10.1039/c6cp03053j] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Optically induced electron transfer is about 3–4 orders of magnitude faster than thermally induced ET in organic mixed valence compounds.
Collapse
|
88
|
Boban A, Henrard S, Lambert C, Hermans C. Continuous infusion of factor VIII concentrates in obese patients with severe haemophilia A: is weight-based dose-adjustment required? Haemophilia 2015; 22:e62-4. [DOI: 10.1111/hae.12837] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2015] [Accepted: 09/29/2015] [Indexed: 11/28/2022]
|
89
|
Taussky D, Bahary J, Lambert C, Beauchemin M, Delouya G, Barkati M, Liem X. Are Results From Intermediate-Risk Prostate Cancer Patients Treated Within Clinical Trials Applicable to Real Life? Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
90
|
Liem X, Bahary J, Delouya G, Beauchemin M, Lambert C, Barkati M, Taussky D. Validité externe des essais cliniques : les résultats pour les cancers de prostate à risque intermédiaire sont-ils applicable à la pratique courante ? Cancer Radiother 2015. [DOI: 10.1016/j.canrad.2015.07.129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
91
|
McLean M, Lambert C, Gevers E, Cowlard J, Chaudry R, Nwokoro C. 179 12 years too late? Rethinking CFRD screening. J Cyst Fibros 2015. [DOI: 10.1016/s1569-1993(15)30356-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
92
|
Boban A, Lambert C, Hermans C. The use of short-term central venous catheters for optimizing continuous infusion of coagulation factor concentrate in haemophilia patients undergoing major surgical procedures. Haemophilia 2015; 21:e364-8. [DOI: 10.1111/hae.12722] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/15/2015] [Indexed: 11/27/2022]
|
93
|
Berthoux FC, Alamartine E, Laurent B, Berthoux P, Vacherot C, Lambert C, Le Petit JC. Primary IgA glomerulonephritis and MHC revisited. CONTRIBUTIONS TO NEPHROLOGY 2015; 104:54-60. [PMID: 8325034 DOI: 10.1159/000422396] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
94
|
Tétreault-Laflamme A, Nguyen T, Vincent F, Saad F, Benoit N, Fortin B, Lambert C, Jolicoeur M. PO-1048: HDR brachytherapy combined to EBRT for prostate cancer: analysis of toxicities and PSA bounce of a phase II trial. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41040-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
95
|
Selleslag D, Lambert C, Zachee P, Huyngh P, Van de Velde A, Noens L, Baily L, André M, Willems E, Dierickx D. Plerixafor prescription modalities in autologous haematopoietic stem cell mobilization in Belgium. Acta Clin Belg 2015; 70:16-22. [PMID: 25236359 DOI: 10.1179/2295333714y.0000000077] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
OBJECTIVES The efficacy and safety of plerixafor, an antagonist of the CXCR4 receptor, in combination with G-CSF has been demonstrated in patients suffering from Iymphoma and multiple myeloma (MM) eligible for autologous haematopoietic stem cell collection. However, different reimbursement criteria have been applied in different countries to select patients eligible for treatment with plerixafor. The objective of this observational study was to describe the plerixafor prescription modalities in daily practice in Belgium. METHODS This open-label, prospective, observational study was conducted in 11 Belgian centres in 114 patients with lymphoma (Hodgkin's and non-Hodgkin's lymphoma) or MM who were treated with plerixafor according to the SmPC between April 2011 and October 2012. Patients included in another clinical trial with plerixafor were excluded from the study. RESULTS The use of plerixafor in patients with MM or lymphoma was effective, with a success rate (defined as a total yield >2×10(6) CD34+ cells/kg) of 77%, and well tolerated (one SAE reported). Optimal collection (defined as a total yield >4×10(6) CD34+ cells/kg) was obtained for 43% of the study population (31% in lymphoma patients, compared to 61% in patients with MM). The use of plerixafor was in line with the SmPC and the Belgian reimbursement criteria for all patients. CONCLUSION This study is showing that the use of plerixafor according to Belgian reimbursement criteria results in similar efficacy and safety as in other centres and countries worldwide.
Collapse
|
96
|
Lambert C, Sarrat A, Bienvenu F, Brabant S, Nicaise-Roland P, Alyanakian MA, Apoil PA, Capron C, Couderc R, Evrard B, Jaby D, Hémont C, Lainé C, Lelong M, Mariotte D, Martinet J, Rénier G, Sainte-Laudy J, Tabary T, Treiner E, Uring-Lambert B, Vigneron C, Vivinus M, Witthuhn F, Vitte J. The importance of EN ISO 15189 accreditation of allergen-specific IgE determination for reliable in vitro allergy diagnosis. Allergy 2015; 70:180-6. [PMID: 25394543 DOI: 10.1111/all.12546] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/09/2014] [Indexed: 01/05/2023]
Abstract
BACKGROUND Allergen-specific serum immunoglobulin E detection and quantification have become an important step in allergy diagnosis and follow-up. In line with the current trend of laboratory test accreditation to international standards, we set out to design and assess an accreditation procedure for allergen-specific serum IgE. METHODS Method validation according to the accreditation procedure under the EN ISO 15189 standard was carried out for allergen-specific immunoglobulin E determination using the fluoroimmunoenzymatic method ImmunoCAP(®) (ThermoFisher). Data were produced by 25 hospital laboratories in France. A total of 29 allergen specificities including mixes, extracts, and molecular allergens were assayed. Allergen-specific serum immunoglobulin E concentrations ranged from 0.1 to 100 kUA /l. RESULTS Repeatability, reproducibility, and accuracy results fulfilled method validation criteria for automated laboratory tests and proved similar irrespective of the allergen specificity, allergen-specific serum immunoglobulin E concentration, or individual laboratory. CONCLUSION Allergen-specific serum immunoglobulin E determination with the fluoroimmunoenzymatic method ImmunoCAP(®) is a highly repeatable, reproducible, and accurate method which may be considered as a single analyte assay in view of the EN ISO 15189 accreditation procedure.
Collapse
|
97
|
Hoton D, Camboni A, Lambert C, Piessevaux H, Mavrogenis G, Jouret-Mourin A. Erratum to: A large polyp in the rectum: not always an epithelial lesion. Int J Colorectal Dis 2015; 30:149. [PMID: 25339135 DOI: 10.1007/s00384-014-2039-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
|
98
|
Betoret I, Lambert C, Paravisini A, Tribaldos M, Paz S, Lizán L. The Burden Of Chronic Urticaria In Europe: A Systematic Literature Review. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2014; 17:A611-A612. [PMID: 27202133 DOI: 10.1016/j.jval.2014.08.2144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
|
99
|
Lecavalier-Barsoum M, Duclos M, Lambert C, David M, Panet-Raymond V, Shin N, Abdulkarim B, Roussel S, Raffis N, Hijal T. Nouveau maillot de corps de support pour irradiation de seins ptosés. Cancer Radiother 2014. [DOI: 10.1016/j.canrad.2014.07.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
100
|
Lambert C, Wagener R, Klein JH, Grelaud G, Moos M, Schmiedel A, Holzapfel M, Bruhn T. A photoinduced mixed-valence state in an organic bis-triarylamine mixed-valence compound with an iridium-metal-bridge. Chem Commun (Camb) 2014; 50:11350-3. [DOI: 10.1039/c4cc04885g] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|